Cosmetic composition comprising carnitine salicylate as active ingredient

Abstract

To provide a cosmetic composition exhibiting acne-mitigating and keratin-peeling effects as a skin-improving material by the ion pairing of carnitine and salicylate under a weakly acidic condition, and simultaneously mitigating inflammation and erythema as a skin-soothing material.SOLUTION: To provide a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.SELECTED DRAWING: Figure 1-1

Description

[Technical Field]

[0001] The present invention relates to a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient. [Background technology]

[0002] Skin aging is a process of gradual and continuous physiological changes caused by exposure to the external environment (extrinsic aging) and genetic factors (intrinsic aging). Skin tissue, among many other tissues in the human body, is constantly exposed to sunlight, which can lead to the death of epidermal stem cells, pigmentation due to melanocyte aging, and degradation of collagen and elastin, components of the epidermis that are associated with skin wrinkles. Furthermore, external stimuli such as sunlight can induce inflammation through the promotion of cytokine secretion, resulting in pain such as erythema, pain, and itching, as well as accelerated skin aging. A variety of substances have been used in cosmetics to alleviate skin diseases and aging caused by such external stimuli. For example, substances such as retinoids, hydroquinone, L-ascorbic acid, and α-hydroxy acids (AHAs) are known to be effective in alleviating aging, while substances such as D-panthenol and glycyrrhizinic acid are known to be effective in alleviating inflammation. In particular, salicylates, also known as beta-hydroxy acids (BHA), are known to have anti-aging and anti-inflammatory properties and have been used since Egypt in 1550 BC. They have been gaining attention as cosmetic ingredients due to their antibacterial properties against P. acnes. However, salicylates are acidic in aqueous solution (pH 3.0 or less), and repeated application to the skin can cause irritation. For this reason, the Cosmetic Ingredient Review Expert Panel recommends using salicylates in their salicylate form at pH 3.5 or higher and applying them in cosmetics at concentrations of 3.0% or less. However, when salicylates are applied in their ionized form in a weakly acidic state, they are known to have limitations, such as reduced skin permeability and efficacy, making it difficult to experience their high efficacy without causing skin irritation. In addition, since salicylate has low solubility in weakly acidic water, prior art methods have been devised to (i) convert it into a salt form, (ii) derivatize it, or (iii) dissolve it in strongly acidic water and then neutralize it to a weak acid. However, when these three methods are applied, the inherent bactericidal effect of salicylate cannot be fully exerted.

[0003] A topical skin preparation containing carnitine has been disclosed that shows acne-reducing effects (Korean Patent Publication No. 10-2010-0095447), and a method of incorporating carnitine into a cosmetic composition at a high content by incorporating it into a hydroxyalkylated salicylic acid cyclodextrin to improve its solubility in water (Korean Patent Registration No. 10-2307186), and it is also known that a cosmetic composition containing a salicylic acid derivative exhibits skin whitening effects by suppressing tyrosinase activity (Korean Patent Publication No. 10-2017-0076091).

[0004] However, the conventional techniques not only involve complicated processes, but also have the drawback of making it difficult to maintain the inherent effectiveness of each component in terms of purpose and effect. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Republic of Korea Patent Publication No. 10-2010-0095447 [Patent Document 2] Republic of Korea Patent No. 10-2307186 [Patent Document 3] Republic of Korea Patent Publication No. 10-2017-0076091 Summary of the Invention [Problem to be solved by the invention]

[0006] Under the above circumstances, the present inventors have confirmed that carnitine salicylate (CA-SA) as an active ingredient can be used as a skin-improving material by ion pairing of carnitine and salicylate under weakly acidic conditions, and can exhibit acne-relieving and exfoliating effects, while also being able to alleviate inflammation and erythema as a skin-soothing material, thereby completing the present invention.

[0007] The object of the present invention therefore relates to a cosmetic composition comprising carnitine salicylate (CA-SA) as an active ingredient. [Means for solving the problem]

[0008] As a means for solving the above problems, the present invention provides a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

[0009] To achieve the above object, a method is provided for alleviating acne and exfoliating the skin through skin improvement, while simultaneously alleviating inflammation and erythema through skin soothing, which comprises the step of applying a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient to the skin.

[0010] To achieve the above object, a method is provided for alleviating acne and exfoliating the skin through skin improvement, while simultaneously alleviating inflammation and erythema through skin soothing, comprising administering to a subject a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

[0011] To achieve the above object, the present invention provides a use of a composition containing carnitine salicylate (CA-SA) as an active ingredient for producing a cosmetic that shows acne relief and exfoliation effects through skin improvement, while also alleviating inflammation and erythema through skin soothing.

[0012] The configuration of the present invention will be described in detail below.

[0013] The present invention relates to a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

[0014] In the present invention, the carnitine is 4-trimethylamino-3-hydroxybutyric acid, and L-carnitine, DL-carnitine, their hydrochlorides, and their derivatives can be used. Preferably, L-carnitine is used.

[0015] Carnitine has been reported to be a mild amino acid exfoliant that is more effective than alpha-hydroxy acids (AHAs) under mildly acidic and neutral conditions. It also has an ammonium group in its structure, which is beneficial for skin permeation and allows it to penetrate the stratum corneum easily.

[0016] A topical skin preparation containing carnitine and exhibiting acne-reducing effects has been disclosed (Korean Patent Publication No. 10-2010-0095447). However, this prior art only uses carnitine as an additive to promote ceramide synthesis, and the compounding ratio is different, so it is not considered to be a major active ingredient. Furthermore, regarding the acne-reducing effect, only the results of acne bacteria experiments and sensory evaluation experiments are described, and no objective results based on standard test methods are presented regarding the cytotoxicity, exfoliation, inflammation-reducing, and erythema-reducing efficacy of the topical skin preparation.

[0017] In one embodiment of the present invention, carnitine salicylate (CA-SA) was prepared and subjected to in vitro and in vivo efficacy tests. As a result, it was found that it has almost no cytotoxicity and is non-irritating to the skin, and as a skin-improving material, it exhibits acne alleviation and exfoliation effects, and at the same time, as a skin-soothing material, it can maximize the effect of alleviating inflammation and erythema.

[0018] Commonly used salicylic acid has low solubility in water, making it difficult to apply at high concentrations in cosmetics, limiting application forms, and potentially causing skin irritation. Therefore, it is recommended to use it in the form of salicylate, but this also has limitations, such as reduced skin permeability and efficacy when applied as a weak acid.

[0019] A method for incorporating salicylic acid into cosmetic compositions at high concentrations by incorporating it into hydroxyalkylated cyclodextrins to improve its water solubility is known (Korean Patent Registration No. 10-2307186). It is also known that cosmetic compositions containing salicylic acid derivatives exhibit skin whitening effects by inhibiting tyrosinase activity (Korean Patent Publication No. 10-2017-0076091). However, the prior art only describes cosmetic compositions containing salicylic acid as a derivative. Furthermore, the prior art only describes tyrosinase inhibition results and sensory evaluation test results regarding skin improvement effects, and does not provide objective results based on standard test methods regarding the cytotoxicity, acne relief, exfoliation, inflammation relief, and erythema relief efficacy of topical agents.

[0020] In one embodiment of the present invention, carnitine salicylate (CA-SA) was prepared and subjected to in vitro and in vivo efficacy tests. As a result, it was found that it has almost no cytotoxicity and is non-irritating to the skin, and as a skin-improving material, it exhibits acne alleviation and exfoliation effects, and at the same time, as a skin-soothing material, it can maximize the effect of alleviating inflammation and erythema.

[0021] In the present invention, salicylic acid is not used in the form of a salt, but rather a eutectic mixture can be prepared using carnitine salicylate (CA-SA), which ion-pairs with carnitine. By including carnitine salicylate (CA-SA), the cosmetic composition according to the present invention can be prepared under weakly acidic conditions, thereby exhibiting improved effects beyond the inherent efficacy of each ingredient. Specifically, the skin-improving effect can be improved by 120% or more, 140% or more, or 160% or more compared to a simple mixture. Furthermore, the cosmetic composition according to the present invention includes carnitine salicylate (CA-SA), which can improve the safety of the composition. Furthermore, the cosmetic composition according to the present invention is virtually non-cytotoxic and non-irritating to the skin, and can maximize the effects of alleviating acne and exfoliating as a skin-improving material, as well as the effects of alleviating inflammation and erythema as a skin-soothing material.

[0022] The eutectic mixture refers to a mixture of two or more solid or liquid substances, in which two components with high melting points are mixed to form a complex due to dipole-dipole attraction, dipole-induced dipole attraction, intermolecular hydrogen bonding, or van der Waals interactions between polar molecules. In other words, the bond of a eutectic mixture refers to a bond between molecules (formation of a eutectic mixture) that occurs while maintaining the individual molecular structures based on hydrogen bonding and dipole-dipole bonding due to partial charges of the molecules.

[0023] The eutectic mixture can be formed by bonding polar compounds together. The polar compounds can be strong acid molecules or charged molecules. There must be a difference in polarity between the polar compounds; identical compounds cannot form a eutectic mixture.

[0024] The ratio of the substances required for the eutectic mixture can be determined by the charge of the molecules of the components that make up the eutectic mixture, the type and number of functional groups that the molecules have, and the polarity of the molecules or functional groups. The ratio of the substances required for the eutectic mixture can also be determined by the size and similarity of the molecules.

[0025] In the present invention, the ratio of carnitine salicylate (CA-SA) required for the eutectic mixture was determined based on the charge and functional group of the carnitine and salicylate molecules, and the polarity of the molecule or functional group. The carnitine salicylate (CA-SA) can be mixed at a molar ratio of carnitine:salicylate of 1 to 6:2, for example, 6:2, 5:2, 4:2, 3:2, 2:2, 1:2, 5.5:2, 4.5:2, 3.5:2, 2.5:2, or 1.5:2. Experimental Example 1-1 confirmed that carnitine salicylate (CA-SA) was stable within this molar ratio range.

[0026] Carnitine and salicylate can form a eutectic mixture due to dipole-dipole bonding caused by the partial charges of specific functional groups, and can form a eutectic mixture at the molar ratio within the above range through their chemical structures.

[0027] If the molar ratio is deviated from the above range, the stability of carnitine at low temperatures decreases, and salicylate may be precipitated at low temperatures due to the fact that the remaining salicylate molecules that cannot ion-pair with carnitine exceed the solubility in water.

[0028] In the present invention, the carnitine salicylate (CA-SA) may be a transparent phase that does not produce any precipitate when left standing at low temperatures, more specifically, no precipitate may be produced even when left standing at 0°C for 3, 4, 5, or 6 weeks or more.

[0029] In the present invention, the cosmetic composition may be in the form of a common emulsifier or solubilizer. For example, it may have the form of a lotion such as an emulsifier lotion or a nutritious lotion, an emulsion such as a facial lotion or a body lotion, a cream such as a nutritious cream, a moisturizing cream, or an eye cream, an essence, a cosmetic ointment, a balm, a spray, a gel, a pack, a sunscreen, a makeup base, a liquid, solid, or spray type foundation, a powder, a makeup remover such as a cleansing cream, a cleansing lotion, or a cleansing oil, or a cleanser such as a cleansing foam, a soap, or a body wash.

[0030] In addition to the composition of the present invention, the cosmetic product may contain adjuvants commonly used in the field of cosmetology, such as fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, moisturizing agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics.

[0031] The cosmetic formulation may contain a relatively high concentration of the composition of the present invention in the case of wash-off cosmetics such as makeup removers and cleansers, in which the active ingredients remain on the skin for a short period of time. On the other hand, leave-on cosmetics such as lotions, emulsions, creams, and essences, in which the active ingredients remain on the skin for a long period of time, may contain a lower concentration of the composition of the present invention compared to wash-off cosmetics. Although not limited thereto, in one embodiment of the present invention, the composition of the present invention may contain 0.01 to 20 parts by weight of carnitine salicylate (CA-SA) based on the weight of the total composition, for example, 0.01 to 20 parts by weight, 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight.

[0032] If the carnitine salicylate (CA-SA) according to the present invention is contained in an amount of less than 0.01 parts by weight of the total composition, sufficient acne alleviation, stimulating exfoliation, inflammation alleviation, and erythema alleviation effects cannot be expected, and if it is contained in an amount exceeding 20 parts by weight, undesirable reactions such as allergies may occur or there may be problems with skin safety, so this is to prevent these.

[0033] Each of the above-mentioned components contained in the cosmetic composition according to the present invention may be contained in the cosmetic composition according to the present invention within the range not exceeding the maximum usage amount specified in each national cosmetic safety standard.

[0034] The present invention also provides a method for producing a cosmetic composition containing carnitine salicylate (CA-SA).

[0035] The manufacturing method of the present invention will be described in detail below.

[0036] The manufacturing method of the present invention may include the steps of: preparing a mixture of carnitine and salicylic acid; stirring the mixture of carnitine and salicylic acid at 50°C to 70°C to prepare carnitine salicylate (CA-SA); and adding the carnitine salicylate (CA-SA) to prepare a cosmetic composition.

[0037] The step of preparing the mixture of carnitine and salicylic acid may include adding purified water.

[0038] In the step of preparing carnitine salicylate (CA-SA), if the temperature is below 50°C, the eutectic mixture will not be fully formed, and if the temperature exceeds 70°C, the eutectic mixture will be destroyed, reducing the effects of the eutectic mixture.

[0039] The step of preparing carnitine salicylate (CA-SA) may include homogenizing the mixture using a homogenizer until the eutectic mixture becomes a colorless or light brown transparent phase, after which additional purification may be omitted.

[0040] According to the present invention, the components constituting the eutectic mixture are uniformly mixed under the homogenization conditions described above, thereby realizing the skin-improving effect, low irritation to the skin, and excellent safety of the formulation of the eutectic mixture.

[0041] When carnitine salicylate (CA-SA) is completely dissolved, it maintains its liquid state and transparency even after a cooling process. The eutectic mixture prepared in this manner can maintain a transparent liquid phase by being uniformly present without phase separation even at very low temperatures, for example, temperatures below 0°C. Furthermore, the eutectic mixture can maintain its bond without breaking even after repeated freezing and melting processes.

[0042] The step of preparing carnitine salicylate (CA-SA) is carried out at a pH of 3.0 to 7.0. Within this acidity range, it can be sufficiently dissolved and its efficacy can be maintained.

[0043] In the step of preparing carnitine salicylate (CA-SA), a eutectic mixture of carnitine and salicylate in a molar ratio of 1 to 6:2, for example, 6:2, 5:2, 4:2, 3:2, 2:2, 1:2, 5.5:2, 4.5:2, 3.5:2, 2.5:2, or 1.5:2, can be used.

[0044] In the step of preparing the cosmetic composition, carnitine salicylate (CA-SA) may be added in an amount of 0.01 to 20 parts by weight, for example, 0.01 to 20 parts by weight, 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight, based on 100 parts by weight of the total composition.

[0045] The preparation of carnitine salicylate (CA-SA) according to the present invention is not limited by the form of the carnitine and salicylate. [Effects of the Invention]

[0046] The cosmetic composition according to the present invention contains carnitine salicylate (CA-SA) as an active ingredient, and as a skin-improving material, it exhibits acne-relieving and exfoliating effects due to the ion pairing of carnitine and salicylate under weakly acidic conditions, and at the same time, it can act as a skin-soothing material to relieve inflammation and erythema, and also improve skin safety. [Brief explanation of the drawings]

[0047] [Figure 1]Figure 1 shows the results of macroscopic and chemical analysis of carnitine salicylate (CA-SA) according to the present invention. Figure 1(a) shows the results of confirming the macroscopic safety of carnitine salicylate (CA-SA) depending on the molar ratio, Figure 1(b) shows the H NMR spectrum of carnitine, Figure 1(c) shows the H NMR spectrum of salicylate, Figure 1(d) shows the H NMR spectrum of carnitine salicylate (CA-SA), and Figure 1(e) shows the IR spectra of carnitine, salicylate, and carnitine salicylate (CA-SA). [Figure 2] FIG. 2 shows the results of in vitro confirmation of the cytotoxicity of carnitine, salicylate, and carnitine salicylate (CA-SA). [Figure 3] Figure 3 shows the results of in vivo studies on the efficacy of carnitine salicylate (CA-SA) according to the present invention. Figure 3(a) shows the results of examining the exfoliating efficacy of a cosmetic composition containing carnitine salicylate (CA-SA), and Figure 3(b) shows the results of examining the erythema alleviating efficacy of a cosmetic composition containing carnitine salicylate (CA-SA). DETAILED DESCRIPTION OF THE INVENTION

[0048] The present invention relates to a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

[0049] In the present invention, the carnitine is 4-trimethylamino-3-hydroxybutyric acid, and L-carnitine, DL-carnitine, their hydrochlorides, and their derivatives can be used. Preferably, L-carnitine is used.

[0050] Carnitine has been reported to be a mild amino acid exfoliant that is more effective than alpha-hydroxy acids (AHAs) under mildly acidic and neutral conditions. It also has an ammonium group in its structure, which is beneficial for skin permeation and allows it to penetrate the stratum corneum easily.

[0051] A topical skin preparation containing carnitine and exhibiting acne-reducing effects has been disclosed (Korean Patent Publication No. 10-2010-0095447). However, this prior art only uses carnitine as an additive to promote ceramide synthesis, and the compounding ratio is different, so it is not considered to be a major active ingredient. Furthermore, regarding the acne-reducing effect, only the results of acne bacteria experiments and sensory evaluation experiments are described, and no objective results based on standard test methods are presented regarding the cytotoxicity, exfoliation, inflammation-reducing, and erythema-reducing efficacy of the topical skin preparation.

[0052] In one embodiment of the present invention, carnitine salicylate (CA-SA) was prepared and subjected to in vitro and in vivo efficacy tests. As a result, it was found that it has almost no cytotoxicity and is non-irritating to the skin, and as a skin-improving material, it exhibits acne alleviation and exfoliation effects, and at the same time, as a skin-soothing material, it can maximize the effect of alleviating inflammation and erythema.

[0053] Commonly used salicylic acid has low solubility in water, making it difficult to apply at high concentrations in cosmetics, limiting application forms, and potentially causing skin irritation. Therefore, it is recommended to use it in the form of salicylate, but this also has limitations, such as reduced skin permeability and efficacy when applied as a weak acid.

[0054] A method for incorporating salicylic acid into cosmetic compositions at high concentrations by incorporating it into hydroxyalkylated cyclodextrins to improve its water solubility is known (Korean Patent Registration No. 10-2307186). It is also known that cosmetic compositions containing salicylic acid derivatives exhibit skin whitening effects by inhibiting tyrosinase activity (Korean Patent Publication No. 10-2017-0076091). However, the prior art only describes cosmetic compositions containing salicylic acid as a derivative. Furthermore, the prior art only describes tyrosinase inhibition results and sensory evaluation test results regarding skin improvement effects, and does not provide objective results based on standard test methods regarding the cytotoxicity, acne relief, exfoliation, inflammation relief, and erythema relief efficacy of topical agents.

[0055] In one embodiment of the present invention, carnitine salicylate (CA-SA) was prepared and subjected to in vitro and in vivo efficacy tests. As a result, it was found that it has almost no cytotoxicity and is non-irritating to the skin, and as a skin-improving material, it exhibits acne alleviation and exfoliation effects, and at the same time, as a skin-soothing material, it can maximize the effect of alleviating inflammation and erythema.

[0056] In the present invention, salicylic acid is not used in the form of a salt, but rather a eutectic mixture can be prepared using carnitine salicylate (CA-SA), which ion-pairs with carnitine. By including carnitine salicylate (CA-SA), the cosmetic composition according to the present invention can be prepared under weakly acidic conditions, thereby exhibiting improved effects beyond the inherent efficacy of each ingredient. Specifically, the skin-improving effect can be improved by 120% or more, 140% or more, or 160% or more compared to a simple mixture. Furthermore, the cosmetic composition according to the present invention includes carnitine salicylate (CA-SA), which can improve the safety of the composition. Furthermore, the cosmetic composition according to the present invention is virtually non-cytotoxic and non-irritating to the skin, and can maximize the effects of alleviating acne and exfoliating as a skin-improving material, as well as the effects of alleviating inflammation and erythema as a skin-soothing material.

[0057] The term "eutectic mixture" refers to a mixture of two or more solid or liquid substances, and refers to the formation of a complex between two components with high melting points through dipole-dipole attraction, dipole-induced dipole attraction, intermolecular hydrogen bonding, or van der Waals interactions between polar molecules. In other words, the bonding of a eutectic mixture refers to the bonding between molecules (formation of a eutectic mixture) that occurs while maintaining the individual molecular structures based on hydrogen bonding and dipole-dipole bonding due to partial charges of the molecules.

[0058] The eutectic mixture can be formed by bonding polar compounds together. The polar compounds can be strong acid molecules or charged molecules. There must be a difference in polarity between the polar compounds; identical compounds cannot form a eutectic mixture.

[0059] The ratio of the substances required for the eutectic mixture can be determined by the charge of the molecules of the components that make up the eutectic mixture, the type and number of functional groups that the molecules have, and the polarity of the molecules or functional groups. The ratio of the substances required for the eutectic mixture can also be determined by the size and similarity of the molecules.

[0060] In the present invention, the ratio of carnitine salicylate (CA-SA) required for the eutectic mixture was determined based on the charge and functional group of the carnitine and salicylate molecules, and the polarity of the molecule or functional group. The carnitine salicylate (CA-SA) can be mixed at a molar ratio of carnitine:salicylate of 1 to 6:2, for example, 6:2, 5:2, 4:2, 3:2, 2:2, 1:2, 5.5:2, 4.5:2, 3.5:2, 2.5:2, or 1.5:2. Experimental Example 1-1 confirmed that carnitine salicylate (CA-SA) was stable within this molar ratio range.

[0061] Carnitine and salicylate can form a eutectic mixture due to dipole-dipole bonding caused by the partial charges of specific functional groups, and can form a eutectic mixture at the molar ratio within the above range through their chemical structures.

[0062] If the molar ratio is deviated from the above range, the stability of carnitine at low temperatures decreases, and salicylate may be precipitated at low temperatures due to the fact that the remaining salicylate molecules that cannot ion-pair with carnitine exceed the solubility in water.

[0063] In the present invention, the carnitine salicylate (CA-SA) may be a transparent phase that does not produce any precipitate when left standing at low temperatures, more specifically, no precipitate may be produced even when left standing at 0°C for 3, 4, 5, or 6 weeks or more.

[0064] In the present invention, the cosmetic composition may be in the form of a common emulsifier or solubilizer. For example, it may have the form of a lotion such as an emulsifier lotion or a nutritious lotion, an emulsion such as a facial lotion or a body lotion, a cream such as a nutritious cream, a moisturizing cream, or an eye cream, an essence, a cosmetic ointment, a balm, a spray, a gel, a pack, a sunscreen, a makeup base, a liquid, solid, or spray type foundation, a powder, a makeup remover such as a cleansing cream, a cleansing lotion, or a cleansing oil, or a cleanser such as a cleansing foam, a soap, or a body wash.

[0065] In addition to the composition of the present invention, the cosmetic product may contain adjuvants commonly used in the field of cosmetology, such as fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, moisturizing agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics.

[0066] The cosmetic formulation may contain a relatively high concentration of the composition of the present invention in the case of wash-off cosmetics such as makeup removers and cleansers, in which the active ingredients remain on the skin for a short period of time. On the other hand, leave-on cosmetics such as lotions, emulsions, creams, and essences, in which the active ingredients remain on the skin for a long period of time, may contain a lower concentration of the composition of the present invention compared to wash-off cosmetics. Although not limited thereto, in one embodiment of the present invention, the composition of the present invention may contain 0.01 to 20 parts by weight of carnitine salicylate (CA-SA) based on the weight of the total composition, for example, 0.01 to 20 parts by weight, 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight.

[0067] If the carnitine salicylate (CA-SA) according to the present invention is contained in an amount of less than 0.01 parts by weight of the total composition, sufficient acne alleviation, stimulating exfoliation, inflammation alleviation, and erythema alleviation effects cannot be expected, and if it is contained in an amount exceeding 20 parts by weight, undesirable reactions such as allergies may occur or there may be problems with skin safety, so this is to prevent these.

[0068] Each of the above-mentioned components contained in the cosmetic composition according to the present invention may be contained in the cosmetic composition according to the present invention within the range not exceeding the maximum usage amount specified in each national cosmetic safety standard.

[0069] The present invention also provides a method for producing a cosmetic composition containing carnitine salicylate (CA-SA).

[0070] In another aspect, a method is provided for alleviating acne and exfoliating the skin through skin improvement, while simultaneously alleviating inflammation and erythema through skin soothing, which comprises the step of applying a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient to the skin.

[0071] In another aspect, there is provided a method for alleviating acne and exfoliating the skin through skin improvement, while simultaneously alleviating inflammation and erythema through skin soothing, comprising the step of administering to a subject a cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

[0072] In another aspect, there is provided a use of a composition containing carnitine salicylate (CA-SA) as an active ingredient for producing a cosmetic that exhibits acne relief and exfoliation effects through skin improvement, while also alleviating inflammation and erythema through skin soothing.

[0073] The manufacturing method of the present invention will be described in detail below.

[0074] The manufacturing method of the present invention may include the steps of: preparing a mixture of carnitine and salicylic acid; stirring the mixture of carnitine and salicylic acid at 50°C to 70°C to prepare carnitine salicylate (CA-SA); and adding the carnitine salicylate (CA-SA) to prepare a cosmetic composition.

[0075] The step of preparing the mixture of carnitine and salicylic acid may include adding purified water.

[0076] In the step of preparing carnitine salicylate (CA-SA), if the temperature is below 50°C, the eutectic mixture will not be sufficiently formed, and if the temperature exceeds 70°C, the eutectic mixture will be destroyed and the effects of the eutectic mixture will be reduced.

[0077] The step of preparing carnitine salicylate (CA-SA) may include homogenizing the mixture using a homogenizer until the eutectic mixture becomes a colorless or light brown transparent phase, after which additional purification may be omitted.

[0078] According to the present invention, the components constituting the eutectic mixture are uniformly mixed under the homogenization conditions described above, thereby realizing the skin-improving effect, low irritation to the skin, and excellent safety of the formulation of the eutectic mixture.

[0079] When carnitine salicylate (CA-SA) is completely dissolved, it maintains its liquid state and transparency even after a cooling process. The eutectic mixture prepared in this manner can maintain a transparent liquid phase by being uniformly present without phase separation even at very low temperatures, for example, temperatures below 0°C. Furthermore, the eutectic mixture can maintain its bond without breaking even after repeated freezing and melting processes.

[0080] The step of preparing carnitine salicylate (CA-SA) is carried out at a pH of 3.0 to 7.0. Within this acidity range, it can be sufficiently dissolved and its efficacy can be maintained.

[0081] In the step of preparing carnitine salicylate (CA-SA), a eutectic mixture of carnitine and salicylate in a molar ratio of 1 to 6:2, for example, 6:2, 5:2, 4:2, 3:2, 2:2, 1:2, 5.5:2, 4.5:2, 3.5:2, 2.5:2, or 1.5:2, can be used.

[0082] In the step of preparing the cosmetic composition, carnitine salicylate (CA-SA) may be added in an amount of 0.01 to 20 parts by weight, for example, 0.01 to 20 parts by weight, 0.01 to 1.2 parts by weight, 0.01 to 1.8 parts by weight, 0.01 to 2.5 parts by weight, 0.01 to 4.7 parts by weight, 0.1 to 7.3 parts by weight, 0.01 to 10 parts by weight, 1.2 to 20 parts by weight, or 1.8 to 10 parts by weight, based on 100 parts by weight of the total composition.

[0083] The preparation of carnitine salicylate (CA-SA) according to the present invention is not limited by the form of the carnitine and salicylate. [Example]

[0084] The present invention will be described in detail below through examples. The following examples are merely illustrative of the present invention, and the scope of the present invention is not limited to the following examples. The examples are provided to complete the disclosure of the present invention and to fully inform those skilled in the art of the present invention of the scope of the invention, and the present invention is defined only by the scope of the claims.

[0085] Production Example 1. Production of carnitine salicylate (CA-SA)

[0086] Carnitine and salicylate were mixed at a molar ratio of 1-6:2, and a small amount of purified water was added and stirred at 50-70°C until the mixture became homogeneous and transparent. Each preparation had a final salicylate content of 0.5% and a weakly acidic pH of 5.5. No further purification was performed. The eutectic mixture solution, which had stably formed ion pairing, was free of precipitates.

[0087] Experimental Example 1: Analysis of Carnitine Salicylate (CA-SA)

[0088] <Experimental Example 1-1> Evaluation of the solubility and safety of carnitine salicylate (CA-SA)

[0089] To confirm the safety of carnitine salicylate (CA-SA), the carnitine salicylate (CA-SA) prepared in the above Preparation Example was left to stand at 25°C and 0°C for 4 weeks, and the safety was evaluated by observing macroscopic changes in properties. After 4 weeks, the presence or absence of phase separation and precipitation was observed with the naked eye, and the results are shown in Table 1 below and Figure 1(a).

[0090] [Table 1]

[0091] CA: Carnitine

[0092] SA: Salicylate

[0093] As shown in Table 1 and Figure 1(a), the results of Examples 1 to 4 confirmed that carnitine salicylate (CA-SA) was stable when the molar ratio of carnitine:salicylate was 1 to 6:2. In Comparative Example 1, where the ratio of carnitine:salicylate was 1:3, salicylate remained in excess of its solubility in water, and thus it was determined that it precipitated at low temperatures.

[0094] Based on the above results, it is concluded that carnitine salicylate (CA-SA) is stable at room temperature and low temperature, and therefore can be applied to cosmetic compositions.

[0095] <Experimental Example 1-1> 1H-NMR analysis

[0096] To compare the structures of carnitine salicylate and carnitine salicylate (CA-SA), 1H-NMR spectra were measured at 500 MHz using an Avance III-500 (NMR spectrometer, Bruker Instruments, USA) at 35°C. Samples were prepared in DO for 1H-NMR measurements. Measurements were performed under the following conditions: 90° pulse width, 12.2 μs; relaxation delay, 4 s; scan time, 100 times. Tetramethylsilane was used as a standard. Carnitine salicylate (CA-SA) was structurally analyzed using Example 2 of Experimental Example 1-1. The results are shown in Figure 1(b), Figure 1(c), and Figure 1(d).

[0097] Figures 1(b), 1(c), and 1(d) show the 1H-NMR spectra of the individual components of carnitine salicylate (CA-SA) and carnitine salicylate (CA-SA). A decrease in the number of split peaks was observed after the formation of carnitine salicylate (CA-SA) in the peak d, which is due to the carnitine spin-spin splitting. A corresponding change was also observed in salicylate, with all peaks a, b, and c shifting upward. The largest upward shift was observed in peak a, suggesting that the functional group participating in the bond between salicylate and carnitine salicylate (CA-SA) is a carboxyl group. It was inferred that carnitine and salicylate form hydrogen bonds in a form that shares protons through the change in the number of hydrogen atoms around the d-hydrogen of carnitine and the intermolecular bonding of the salicylate carboxyl group.

[0098] These results confirmed that carnitine and salicylate were indeed ion-paired.

[0099] <Experimental Example 1-3> FT-IR analysis

[0100] The binding sites between the functional groups of carnitine, salicylate, and carnitine salicylate (CA-SA) were analyzed through FT-IR spectrum analysis. FT-IR spectra were obtained using a Vertex70 Hyperion 2000 (FTIR spectrophotometer, Bruker Instruments) model from 3600 to 500 cm. 1 Range: 2cm 1 The spectra were measured at intervals of 100 s. The spectra were then deconvoluted and analyzed using Opus 5.5 software (Bruker Instruments). Carnitine salicylate (CA-SA) was structurally analyzed using Example 2 of Experimental Example 1-1. The results are shown in Figure 1(e).

[0101] As shown in Figure 1(e), the IR spectrum of L-carnitine shows the intensification of IR peaks due to vibrations of the -COOH and -OH groups. The positions of these main peaks are 1396-1385 (COOH), 1245 (CC), 1137-1195 (CCO, COH), 913 (C-COOH), and 625-634 (COH) cm. -1 The band due to the ammonium group also appears characteristically. + The peaks of (CH3)3) are 970, 944 and 772 cm -1 In the case of salicylate, three bands appear characteristically at 3233 cm due to OH and CH, respectively. -1 and 999-2831 cm -1 The characteristic vibration peak of C=O (COO-) is 1652-1670cm -1 and 1386 cm -1 It was also observed at 1558-1610 cm -1 In this case, a peak due to C=C (phenol group) is observed, and 1324 OH (phenol group) cm -1 , 1296(COO-(CO))cm -1 and 1156-1248 C-OH(phenol group)cm -1 After the formation of carnitine salicylate (CA-SA), the changes in these peaks were confirmed, revealing the peaks at 1137-1195 (CCO, COH) and 625-634 (COH) cm of carnitine. -1 Peak of salicylate 1652-1670 C=O(COO-)cm -1 Changes in the spectrum shape due to intermolecular bonding can be observed at this position. Based on this, as with the 1H-NMR analysis results, it was determined that carnitine salicylate (CA-SA) forms hydrogen bonds in the form of proton sharing between the OH and COO- groups of carnitine and salicylate.

[0102] These results confirmed that carnitine and salicylate were indeed ion-paired.

[0103] Experimental Example 2: Evaluation of the in vitro exfoliation, cytotoxicity, and anti-inflammatory efficacy of carnitine salicylate (CA-SA)

[0104] <Experimental Example 2-1> Confirmation of the in vitro exfoliating effect of carnitine salicylate (CA-SA)

[0105] To compare the exfoliating efficacy of carnitine (CA), salicylate (SA), a simple mixture of carnitine and salicylate (SA+CA, MIX), and carnitine salicylate (SA-CA), their relative keratinization efficacy was evaluated in vitro using pig dorsal skin (Apures, Rep. of Korea) at a mildly acidic pH of 5.5, which does not induce skin irritation. The surface of the pig dorsal skin was washed with phosphate buffered silane (PBS) and cut to size. The stratum corneum of the pig skin was then exposed and placed in a 96-well plate. 100 μl of each sample was applied, and the 96-well plate was then placed in a temperature- and humidity-controlled chamber for 16 hours. The supernatant of each sample was then thoroughly mixed with trypan blue solution in the 96-well plate, and the number of detached corneocytes was measured. The following method was used to verify the suitability of the relative keratinization efficacy evaluation method used in this study. DL-gluconolactone at pH 4.0 and 6.0 was used as a positive control. After treating pig skin with the samples as described above, the number of exfoliated keratinocytes was counted and the relative exfoliation efficacy was evaluated, with the number of exfoliated keratinocytes exfoliated by PHA (DL-gluconolactone) at pH 4.0 set at 100%. All evaluations were performed with n=5 to ensure reliability through repeated results. The exfoliation efficacy was compared using the mean and standard deviation of the number of exfoliated keratinocytes, and the results are shown in Table 2.

[0106] [Table 2]

[0107] As shown in Table 2, when compared relative to the efficacy of 10.0% gluconolactone at pH 4.0 (set at 100%), carnitine salicylate (CA-SA) demonstrated 91.8% exfoliation efficacy. Meanwhile, the same amount of salicylate demonstrated 19.2%, carnitine 55.2%, and a simple mixture of carnitine and salicylate (CA+SA, MIX) 56.5% exfoliation efficacy. These results demonstrate that carnitine salicylate (CA-SA) has significant exfoliation efficacy even in a mildly acidic environment with minimal irritation.

[0108] <Experimental Example 2-2> Confirmation of in vitro cytotoxicity of carnitine salicylate (CA-SA)

[0109] The cytotoxicity of carnitine salicylate (CA-SA) was evaluated using the 3-(4,5-dimethythiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay. Raw264.7 cell line and fibroblasts derived from human skin tissue were cultured in 24-well plates at 1–2 x 10 in DMEM medium supplemented with 10% FBS. 5 The cells were seeded at a concentration of 1000 cells / ml and cultured for 24 hours in a 5% CO2 incubator. The medium was removed, and each sample was added to medium without FBS and cultured for 24 hours. After that, the medium was removed, and MTT solution was added at a concentration of 1 μg / ml and reacted at 37°C for 3 hours. Unreacted MTT solution was removed, and 100 μl of DMSO was added to dissolve the reactant. The absorbance was measured at 540 nm to confirm cytotoxicity.

[0110] The cytotoxicity of salicylate, carnitine, and carnitine salicylate (CA-SA) was evaluated by treating the materials with Raw264.7 mouse macrophages and human fibroblasts. Raw264.7 is a representative cell line used to measure NO inhibitory activity as an anti-inflammatory agent, and cytotoxicity was evaluated against these cells. Fibroblasts were evaluated to assess potential toxicity induced by repeated application of cosmetic materials to the skin. Carnitine salicylate (CA-SA) was evaluated using Example 2 of Experimental Example 1-1, based on the salicylic acid content in the eutectic mixture, not the carnitine salicylate (CA-SA) content. The results are shown in Figure 2.

[0111] As shown in Figure 2, when salicylate was treated with Raw 264.7, cell activity was 96.16% in cells treated with 50 ppm and 79.74% in cells treated with 100 ppm. In the case of fibroblasts, cell activity was 94.83% in cells treated with 50 ppm and 85.36% in cells treated with 100 ppm. This indicates that salicylate can induce cytotoxicity when treated at 50 ppm or higher at the cellular level. However, carnitine and carnitine salicylate (CA-SA) showed cell activity of over 95% throughout the entire concentration range up to 100 ppm, indicating no cytotoxicity.

[0112] Based on the above results, it is concluded that the ion pairing of carnitine and salicylate prevents the cytotoxicity inherent in each component, and therefore has little effect on cell activity, making it safe for use on the human body.

[0113] <Experimental Example 2-3> Confirmation of the in vitro anti-inflammatory effect of carnitine salicylate (CA-SA)

[0114] A test was conducted to confirm the anti-inflammatory effect of carnitine salicylate (CA-SA). Based on the results of Experimental Example 2-2, the anti-inflammatory effects of salicylate, carnitine, and carnitine salicylate (CA-SA) were evaluated through their NO inhibitory effects at 10 ppm, a concentration at which none of the materials exhibit cytotoxicity. The cells were treated with 500 ng / ml of lipopolysaccharide (LPS), an inflammation inducer, and 100 mM of NG-monomethyl-L-arginine acetate (L-NMMA), a nitric oxide synthase (NOS) inhibitor, as a positive control, to confirm the NO inhibitory rate.

[0115] To evaluate the efficacy of reducing inflammation caused by external stimuli in vitro, Raw264.7 (ATCC number: CRL-2788), a mouse macrophage cell line, was treated with lipopolysaccharides (LPS, Sigma-Aldrich, USA) and then the GRIESS method was used to evaluate the inhibition of NO production. Raw264.7 cells were pre-cultured in growth medium (DMEM supplemented with 10% FBS, Welgene, USA) and plated at 1-2 x 10 cells per well in a 24-well tissue culture plate. 5 The cells were added at a concentration of 1000 cells / ml and cultured in a 5% CO2 incubator for one day. The medium was removed, and the cells were starvated in serum-free medium for 12 hours. After pretreatment with the test substance at 0.1 to 100 ppm for 30 minutes, LPS was added at a concentration of 500 ng / ml and cultured for 18 hours. After culture, the supernatant was transferred to a 96-well plate, and GRIESS reagent was added and incubated at room temperature for 15 minutes. The absorbance at 540 nm was measured using an ELISA reader. Carnitine salicylate (CA-SA) was prepared as described in Example 2 of Experimental Example 1-1. The results are shown in Table 3.

[0116] [Table 3]

[0117] As shown in Table 3, salicylate exhibited an NO inhibitory effect of 16.4%, carnitine 0.0%, a simple mixture of carnitine and salicylate (SA+CA) 20.4%, and carnitine salicylate (CA-SA) 60.0%. These results demonstrate that carnitine salicylate (CA-SA) of the present invention exhibits superior anti-inflammatory efficacy through ion pairing compared to the inherent anti-inflammatory efficacy of each component. This confirms that it is an advanced material that can also exhibit skin soothing efficacy against irritation that may be induced by the inherent exfoliating effect of each component.

[0118] <Experimental Example 2-4> Confirmation of the in vitro bactericidal effect of carnitine salicylate (CA-SA) on acne bacteria

[0119] The anti-P. acnes activity of carnitine salicylate (CA-SA) was confirmed through a time-killing assay. 6 Bacteria were inoculated to a concentration of CFU / ML. 20 minutes, 1 hour, 3 hours, and 6 hours after inoculation, 1 ml of each sample was sampled and diluted in D / E solution to remove the antiseptic properties. Each sample was diluted to an appropriate dilution factor and plated on mLNA medium. Each sample was cultured in an incubator at 30°C for at least 48 hours, and the number of bacteria on the plate was counted. Samples were prepared as shown in Table 4 below, and the results are shown in Table 5 below.

[0120] [Table 4]

[0121] SA: salicylate, CA: carnitine, CA-SA: carnitine salicylate

[0122] [Table 5]

[0123] As shown in the above results, when comparing the sterilization rate of Propionibacterium acnes in Comparative Examples 2 and 3, which are each single component, under weakly acidic conditions, Example 5 was found to be significantly higher, and was at a similar level to Comparative Example 4, which had the lowest pH despite being weakly acidic. Therefore, it is believed that carnitine salicylate (CA-SA) according to the present invention can sufficiently eliminate Propionibacterium acnes even in weakly acidic conditions, thereby improving acne-prone skin without irritation.

[0124] Experimental Example 3: Evaluation of the in vivo exfoliation and erythema suppression effects of carnitine salicylate (CA-SA)

[0125] <Experimental Example 3-1> Confirmation of the in vivo exfoliating effect of carnitine salicylate (CA-SA)

[0126] To evaluate the exfoliating efficacy of carnitine salicylate (CA-SA), a clinical study was conducted on six randomly selected volunteers (ages: 25-35). A 5.0% DHA patch was applied to the subject's forearm and left on for 24 hours to stain the keratin. The stained areas were evaluated using a colorimeter (CR-400, Konica Minolta, Japan), and four areas with the same staining level were selected. A carnitine salicylate (CA-SA) solution (Example 6) and a base solution (Comparison 5) containing no sample were applied twice daily to the same areas, morning and evening, for 14 days. One area was left untreated for comparison. All areas were maintained under the same conditions, and no additional physical or chemical exfoliation was performed during the evaluation period. The exfoliating efficacy was evaluated based on the change in brightness of the stained areas after 7 and 14 days using a colorimeter. Exfoliating efficacy was evaluated as follows:

[0127]

number

[0128] Statistical significance was analyzed using a paired t-test. The base for evaluation was prepared without materials that may affect keratin exfoliation, inflammation induction, or relief, and the results are shown in Figure 3(a).

[0129] [Table 6]

[0130] As shown in Figure 3(a), the non-application and base formulation application groups (Comparative Example 5) showed improvement rates of 4.65%, 10.41%, 43.00%, and 47.30% on the 7th and 14th days, respectively. The carnitine salicylate (SA-CA) application group (Example 6) showed improvement rates of 49.16% and 65.49%, and it was confirmed that carnitine salicylate (SA-CA) application improved the exfoliation effect by 38.46% on the 14th day compared to the base application group.

[0131] Based on the above results, it is concluded that the inclusion of carnitine salicylate (SA-CA) according to the present invention in a cosmetic composition can exhibit exfoliating effects when applied to the human body.

[0132] <Experimental Example 3-2> Confirmation of the in vivo erythema suppression effect of carnitine salicylate (SA-CA)

[0133] A test to confirm the efficacy of erythema suppression was conducted using Example 6 of Experimental Example 3-1. To evaluate the efficacy of erythema suppression, 9 random volunteers (ages: 25-35) were randomly selected and their erythema index was evaluated before and after erythema induction, and 5 and 12 days after product use. A 1% SDS diluted solution was applied to the forearm for 24 hours to damage the skin barrier and induce erythema. A carnitine salicylate (SA-CA) aqueous solution (0.5% salicylate, pH 5.5) and a sample-free base were then applied to the designated areas twice daily, morning and evening, for 12 days. The erythema index was measured after 5 and 12 days using a Mexameter (MX 18, Courage+Khazaka electronic GmbH, Germany), and the erythema index recovery rate was evaluated as follows:

[0134]

number

[0135] Statistical significance was analyzed using a paired t-test, and the results are shown in Figure 3(b).

[0136] As shown in Figure 3(b), after 5 and 12 days, the subjects who did not apply the drug showed recovery rates of 40.32% and 51.82%, respectively, and the subjects who applied the base dosage form showed recovery rates of 46.76% and 59.86%. However, the subjects who applied carnitine salicylate (SA-CA) and Example 6 showed recovery rates of 63.08% after 5 days and 74.03% after 12 days, confirming that the erythema recovery rates of 34.90% after 5 days and 23.67% after 12 days were higher than those of the subjects who applied the base dosage form.

[0137] Based on the above results, by including carnitine salicylate (SA-CA) according to the present invention in a cosmetic composition, it is possible to exhibit the efficacy of alleviating inflammation and erythema at the same time when applied to the human body.

[0138] Experimental Example 4: Sensory evaluation of cosmetic compositions containing carnitine salicylate (CA-SA)

[0139] A sensory evaluation test was conducted using Example 6 of Experimental Example 3-1. To evaluate the perceived efficacy of applying a cosmetic composition containing carnitine salicylate (SA-CA) to exfoliate and soothe the skin, the test was conducted on volunteers with sensitive skin who use cosmetics daily and often complain of skin irritation. The volunteers continued to use their usual cosmetics, but after additional face washing, they first applied the cosmetic composition containing carnitine salicylate (SA-CA) according to the present invention. The evaluation was conducted using a 5-point scale (5: very significant improvement, 4: perceived improvement, 3: no noticeable change, 2: perceived worsening, 1: significant worsening), and the results are shown in Table 7 below.

[0140] [Table 7]

[0141] As shown in the above results, after repeated periodic application of a cosmetic composition containing carnitine salicylate (CA-SA, Example 6), it was assessed that skin irritation and erythema were alleviated, and skin texture was improved. The softening of skin texture is believed to be due to sustained exfoliation. These results indicate that the inclusion of carnitine salicylate (CA-SA) in a cosmetic composition not only enables daily exfoliation with low irritation, but also reduces inflammation caused by irritants. [Industrial Applicability]

[0142] The cosmetic composition according to the present invention contains carnitine salicylate (CA-SA) as an active ingredient, and as a skin-improving material, it exhibits acne-relieving and exfoliating effects due to the ion pairing of carnitine and salicylate under weakly acidic conditions, and at the same time, as a skin-soothing material, it can relieve inflammation and erythema, and also improve skin safety.

Claims

1. A cosmetic composition containing carnitine salicylate (CA-SA) as an active ingredient.

2. The cosmetic composition according to claim 1, wherein the cosmetic composition has a pH of 4.0 to 6.

5.

3. The cosmetic composition according to claim 1, wherein the carnitine salicylate (CA-SA) is contained in an amount of 0.01 to 20 parts by weight based on 100 parts by weight of the total composition.

4. 2. The cosmetic composition according to claim 1, wherein the carnitine salicylate (CA-SA) is a eutectic mixture in a molar ratio of carnitine:salicylate=1 to 6:

2.

5. 2. The cosmetic composition according to claim 1, wherein the carnitine salicylate (CA-SA) is free from precipitates when left standing at 0°C for 4 weeks.

6. The cosmetic composition according to claim 1, which is for improving skin.

7. The cosmetic composition according to claim 6, wherein the skin improvement is for alleviating acne.

8. The cosmetic composition according to claim 6, wherein the skin improvement is for promoting exfoliation of keratin.

9. The cosmetic composition according to claim 1, wherein the cosmetic composition is for skin soothing.

10. The cosmetic composition according to claim 9, wherein the skin soothing effect is for alleviating inflammation.

11. The cosmetic composition according to claim 9, wherein the skin soothing effect is for alleviating erythema.

12. preparing a mixture of carnitine and salicylic acid; Stirring the mixture at 50°C to 70°C to produce carnitine salicylate (CA-SA); and A method for producing a cosmetic composition, comprising: adding the carnitine salicylate (CA-SA) to produce a cosmetic composition.

13. The method for producing a cosmetic composition according to claim 12, wherein the step of preparing the mixture of carnitine and salicylic acid includes adding purified water.

14. The method for producing a cosmetic composition according to claim 12, wherein the step of producing the carnitine salicylate (CA-SA) comprises homogenizing the carnitine salicylate (CA-SA) using a homogenizer until the carnitine salicylate becomes a colorless or light brown transparent phase.

15. 13. The method of claim 12, wherein the step of preparing the cosmetic composition comprises adding carnitine salicylate (CA-SA) in an amount of 0.01 to 20 parts by weight based on 100 parts by weight of the total composition.

Images